ARTV advances pivotal Phase III trial for refractory RA
ARTV’s AlloNK cell platform is advancing in a pivotal Phase III trial for refractory RA. Enrollment is robust, with data updates expected by year-end and top-line results targeted for 2028.
The AlloNK cell platform is advancing in a pivotal phase III trial for refractory RA, with the program built around deep B-cell depletion and a favorable safety profile. Enrollment is robust, with data updates expected by year-end and top-line results by 2028. Expansion into Sjögren's and scleroderma is under consideration.